Kong Xinxin, Boeckhaus Jan, Wang Fang, Shi Chunyan, Zhang Hongwen, Gross Oliver, Ding Jie, Zhang Yanqin
Department of Pediatrics, Peking University First Hospital, No. 1 Xi An Men Da Jie, Beijing, 100034, China.
Clinic for Nephrology and Rheumatology, University Medicine Goettingen, Robert-Koch Str. 40, 37075, Goettingen, Germany.
J Nephrol. 2025 Apr;38(3):1085-1092. doi: 10.1007/s40620-025-02252-2. Epub 2025 May 20.
During pregnancy, hyperfiltration and other factors are hypothesized to contribute to the progression of kidney disease in women with Alport syndrome. To evaluate the status of kidney disease, clinical data from mothers with Alport syndrome in China and Europe over the pregnancy were analyzed.
This retrospective observational study collected data to evaluate proteinuria, kidney function and Alport stage prior to, during, and after pregnancy, respectively.
A total of 74 women were enrolled, 82% of them with X-linked Alport syndrome and 11% with autosomal Alport syndrome (unknown in 5 patients). Detailed information on the course of pregnancy was available for 62 pregnancies from 52 different women. No fetal malformations were observed. Mean gestational age was 37.9 ± 2.7 weeks (n = 55). Complications included high blood pressure (n = 8), abortion (n = 5), preeclampsia (n = 5), gestational diabetes (n = 3), nephrotic syndrome (n = 2), cervical insufficiency with fetal growth delay (n = 2), premature rupture of membranes (n = 1) and acute intrauterine fetal distress (n = 1). Median proteinuria was 350 (30-2465) mg/day prior to pregnancy, 2390 (450-11,450) mg/day during pregnancy, and 590 (40-2650) mg/day at a mean postpartum follow-up time of 4.5 ± 2.1 years. Mean estimated glomerular filtration rate (eGFR) decreased by 17.2 ± 16.7 ml/min/1.73 m, from 96.1 ± 32.9 to 78.9 ± 37 ml/min/1.73 m after pregnancy (n = 15; p = 0.003). The eGFR loss was higher in women with eGFR < 90 ml/min/1.73 m prior to pregnancy compared to women with normal renal function (- 21.5 ± 9.8 vs. - 14 ± 20 ml/min/1.73 m), and in women with severe variants compared to women with less severe variants (- 21.5 ± 20.2 vs. - 11.3 ± 19.0 ml/min/1.73 m). Progression of Alport stage after pregnancy was observed in 42% of the women, 31% remained in stage 0-1, and 23% remained in stage 2.
This study provides important data on the natural history of Alport syndrome in women who have undergone a pregnancy. Women with severe variants of Alport syndrome, and women with eGFR below 90 ml/min/1.73 m face greater risks of kidney disease progression after pregnancy. Further prospective studies are required to confirm these findings.
在孕期,超滤过及其他因素被认为会促使患有奥尔波特综合征的女性肾病进展。为评估肾病状况,对中国和欧洲患有奥尔波特综合征的母亲孕期临床数据进行了分析。
这项回顾性观察性研究收集数据,分别评估孕前、孕期及产后的蛋白尿、肾功能和奥尔波特分期。
共纳入74名女性,其中82%为X连锁奥尔波特综合征,11%为常染色体奥尔波特综合征(5例情况不明)。来自52名不同女性的62次妊娠有详细的孕期过程信息。未观察到胎儿畸形。平均孕周为37.9±2.7周(n = 55)。并发症包括高血压(n = 8)、流产(n = 5)、先兆子痫(n = 5)、妊娠期糖尿病(n = 3)、肾病综合征(n = 2)、宫颈机能不全伴胎儿生长受限(n = 2)、胎膜早破(n = 1)和急性胎儿宫内窘迫(n = 1)。孕前蛋白尿中位数为350(30 - 2465)mg/天,孕期为2390(450 - 11450)mg/天,产后平均随访4.5±2.1年时为590(40 - 2650)mg/天。平均估计肾小球滤过率(eGFR)下降了17.2±16.7 ml/min/1.73m²,从孕前的96.1±32.9降至产后的78.9±37 ml/min/1.73m²(n = 15;p = 0.003)。与肾功能正常的女性相比,孕前eGFR<90 ml/min/1.73m²的女性eGFR损失更高(-21.5±9.8 vs. -14±20 ml/min/1.73m²),与病情较轻的女性相比,病情严重的女性eGFR损失更高(-21.5±20.2 vs. -11.3±19.0 ml/min/1.73m²)。42%的女性在产后出现奥尔波特分期进展,31%仍处于0 - 1期,23%仍处于2期。
本研究提供了关于经历过妊娠的女性奥尔波特综合征自然病程的重要数据。患有严重型奥尔波特综合征的女性以及eGFR低于90 ml/min/1.73m²的女性在产后面临肾病进展的更大风险。需要进一步的前瞻性研究来证实这些发现。